4-[3-(4-tert-butylanilino)-2-(hydroxymethyl)phenyl]-N,N,6-trimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[3-(4-tert-butylanilino)-2-(hydroxymethyl)phenyl]-N,N,6-trimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
• 化学式: C₂₈H₃₂N₄O₃
• 分子量: 472.6
• InChiKey: RBUZJLSDEAVRNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  88.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 1H-PYRROLOPYRIDINONE SUBSTITUÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014125408A2

  公开（公告）日：2014-08-21

  The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.